Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment

NCT01747538 | Terminated Phase 3

• 3 other identifiers: X052131/CL3-78989-0062012-001609-25U1111-1135-1462
• Study Type: interventional
• Target: 281
• Locations: 20 countries
• Sites: 112

Brief Summary

The purpose of this study is to evaluate the efficacy of gevokizumab in reducing the risk of recurrent uveitic disease in subjects with non-infectious uveitis whose disease is currently controlled with systemic treatment.

Conditions

Uveitis

Keywords

Uveitis; Non-infectious Uveitis; Intermediate Uveitis; Posterior Uveitis; Panuveitis

Outcome Measures

Primary Outcomes (1)

• Proportion of subjects with an occurrence of uveitic disease through Day 168

  Day 0 through Day 168

Secondary Outcomes (1)

• Time to first occurrence of uveitic disease

  Day 0 through Day 168

Study Arms (3)

Placebo

PLACEBO COMPARATOR

Drug: Placebo

Dose 1 gevokizumab

EXPERIMENTAL

Drug: Dose 1 gevokizumab

Dose 2 gevokizumab

EXPERIMENTAL

Drug: Dose 2 gevokizumab

Interventions

Placebo DRUG

Solution for subcutaneous injection

Placebo

Dose 1 gevokizumab DRUG

Solution for subcutaneous injection

Dose 1 gevokizumab

Dose 2 gevokizumab DRUG

Solution for subcutaneous injection

Dose 2 gevokizumab

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosis of non-infectious intermediate, posterior, or pan- uveitis in at least one eye
• Controlled uveitic disease in both eyes
• Stable dose of oral corticosteroids in combination with selected stable immunosuppressive therapy
• Effective contraceptive measures

You may not qualify if:

• Infectious uveitis and masquerade syndromes
• Isolated anterior uveitis
• Contraindication to mydriatics
• Active tuberculosis disease
• History of allergic or anaphylactic reactions to monoclonal antibodies
• History of recurrent infection or predisposition to infection; active ocular infection
• Pregnant or nursing women

Sponsors & Collaborators

• XOMA (US) LLC: lead
• Institut de Recherches Internationales Servier: collaborator

Study Sites (114)

Unknown Facility

Chandler, Arizona, United States

Location

Unknown Facility

Phoenix, Arizona, United States

Location

Unknown Facility

Beverly Hills, California, United States

Location

Unknown Facility

Los Angeles, California, United States

Location

Unknown Facility

Redlands, California, United States

Location

Unknown Facility

Sacramento, California, United States

Location

Unknown Facility

San Luis Obispo, California, United States

Location

Unknown Facility

Santa Ana, California, United States

Location

Unknown Facility

Victorville, California, United States

Location

Unknown Facility

Golden, Colorado, United States

Location

Unknown Facility

Littleton, Colorado, United States

Location

Unknown Facility

Bridgeport, Connecticut, United States

Location

Unknown Facility

Washington D.C., District of Columbia, United States

Location

Unknown Facility

Lakeland, Florida, United States

Location

Unknown Facility

St. Petersburg, Florida, United States

Location

Unknown Facility

Tampa, Florida, United States

Location

Unknown Facility

Atlanta, Georgia, United States

Location

Unknown Facility

Chicago, Illinois, United States

Location

Unknown Facility

Indianapolis, Indiana, United States

Location

Unknown Facility

Iowa City, Iowa, United States

Location

Unknown Facility

Ellsworth, Maine, United States

Location

Unknown Facility

Baltimore, Maryland, United States

Location

Unknown Facility

Cambridge, Massachusetts, United States

Location

Unknown Facility

Waltham, Massachusetts, United States

Location

Unknown Facility

Detroit, Michigan, United States

Location

Unknown Facility

Jackson, Michigan, United States

Location

Unknown Facility

Royal Oak, Michigan, United States

Location

Unknown Facility

Rochester, Minnesota, United States

Location

Unknown Facility

St Louis, Missouri, United States

Location

Unknown Facility

Omaha, Nebraska, United States

Location

Unknown Facility

Bloomfield, New Jersey, United States

Location

Unknown Facility

Palisades Park, New Jersey, United States

Location

Unknown Facility

Teaneck, New Jersey, United States

Location

Unknown Facility

Belmont, North Carolina, United States

Location

Unknown Facility

Charlotte, North Carolina, United States

Location

Unknown Facility

Winston-Salem, North Carolina, United States

Location

Unknown Facility

Fargo, North Dakota, United States

Location

Unknown Facility

Beachwood, Ohio, United States

Location

Unknown Facility

Cleveland, Ohio, United States

Location

Unknown Facility

Middleburg Heights, Ohio, United States

Location

Unknown Facility

Ashland, Oregon, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, United States

Location

Unknown Facility

Knoxville, Tennessee, United States

Location

Unknown Facility

Memphis, Tennessee, United States

Location

Unknown Facility

Austin, Texas, United States

Location

Unknown Facility

Dallas, Texas, United States

Location

Unknown Facility

Houston, Texas, United States

Location

Unknown Facility

Mission, Texas, United States

Location

Unknown Facility

San Antonio, Texas, United States

Location

Unknown Facility

Salt Lake City, Utah, United States

Location

Unknown Facility

Norfolk, Virginia, United States

Location

Unknown Facility

Olivos, Buenos Aires, Argentina

Location

Unknown Facility

Rosaria, Santa Fe Province, Argentina

Location

Unknown Facility

Buenos Aires, Argentina

Location

Unknown Facility

Yerevan, Armenia

Location

Unknown Facility

Sydney, New South Wales, Australia

Location

Unknown Facility

East Melbourne, Victoria, Australia

Location

Unknown Facility

Nedlands, Western Australia, Australia

Location

Unknown Facility

Darlinghurst, New South Wales, Australia

Location

Unknown Facility

Belo Horizonte, Minas Gerais, Brazil

Location

Unknown Facility

Rio de Janeiro, Brazil

Location

Unknown Facility

São Paulo, Brazil

Location

Unknown Facility

Ottawa, Ontario, Canada

Location

Unknown Facility

Montreal, Quebec, Canada

Location

Unknown Facility

Beijing, China

Location

Unknown Facility

Chongqing, China

Location

Unknown Facility

Hong Kong, China

Location

Unknown Facility

Lyon, France

Location

Unknown Facility

Nantes, France

Location

Unknown Facility

Paris, France

Location

Unknown Facility

Berlin, Germany

Location

Unknown Facility

Chemnitz, Germany

Location

Unknown Facility

Heidelberg, Germany

Location

Unknown Facility

Münster, Germany

Location

Unknown Facility

Tüebingen, Germany

Location

Unknown Facility

Mezourlo, Larissa, Greece

Location

Unknown Facility

Jerusalem, Israel

Location

Unknown Facility

Petoch Tikvah, Israel

Location

Unknown Facility

Tel Aviv, Israel

Location

Unknown Facility

Ancona, Marche, Italy

Location

Unknown Facility

Genova, Italy

Location

Unknown Facility

Milan, Italy

Location

Unknown Facility

Padua, Italy

Location

Unknown Facility

Romagna, Italy

Location

Unknown Facility

Distrito Federal, Mexico

Location

Unknown Facility

Mexico City, Mexico

Location

Unknown Facility

Nuevo León, Mexico

Location

Unknown Facility

Tijuana, Mexico

Location

Unknown Facility

Gdansk, Poland

Location

Unknown Facility

Katowice, Poland

Location

Unknown Facility

Lublin, Poland

Location

Unknown Facility

Warsaw, Poland

Location

Unknown Facility

Braga, Portugal

Location

Unknown Facility

Coimbra, Portugal

Location

Unknown Facility

Lisbon, Portugal

Location

Unknown Facility

Khabarovsk, Russia

Location

Unknown Facility

Novosibirsk, Russia

Location

Unknown Facility

Saint Petersburg, Russia

Location

Unknown Facility

Durban, South Africa

Location

Unknown Facility

Johannesburg, Gauteng, South Africa

Location

Unknown Facility

Barcelona, Spain

Location

Unknown Facility

Granada, Spain

Location

Unknown Facility

Madrid, Spain

Location

Unknown Facility

Málaga, Spain

Location

Unknown Facility

Taïpeï City, Taiwan

Location

Unknown Facility

Taoyuan District, Taiwan

Location

Unknown Facility

Monastir, Tunisia

Location

Unknown Facility

Ankara, Turkey (Türkiye)

Location

Unknown Facility

Cerrahpasa, Istanbul, Turkey (Türkiye)

Location

Unknown Facility

Faith, Istanbul, Turkey (Türkiye)

Location

Unknown Facility

Sunderland, Tyne and Wear, United Kingdom

Location

Unknown Facility

Bristol, United Kingdom

Location

Unknown Facility

Liverpool, United Kingdom

Location

Unknown Facility

London, United Kingdom

Location

MeSH Terms

Conditions

Uveitis; Uveitis, Intermediate; Uveitis, Posterior; Panuveitis

Condition Hierarchy (Ancestors)

Uveal Diseases; Eye Diseases

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 7, 2012
• First Posted: December 11, 2012
• Study Start: October 1, 2012
• Primary Completion: June 1, 2016
• Last Updated: July 12, 2016

Record last verified: 2016-07

Locations

TU (3); ME (4); GB (4); AR (3); AU (4); PL (4); RU (3); ES (4); CA (2); DE (5); TW (2); FR (3); CN (3); BR (3); IL (3); GR (1); IT (5); US (51); PT (3); ZA (2)